PUBLISHER: Polaris Market Research | PRODUCT CODE: 1651966
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1651966
Asia Pacific SGLT2 Inhibitors Market Size, Share, Trends, Industry Analysis Report: By Indication (Cardiovascular, Chronic Kidney Disease, Type 2 Diabetes, and Others), Drug, Distribution Channel, and Country - Market Forecast, 2025- 2034
The Asia Pacific SGLT2 inhibitors market size is expected to reach USD 3,972.35 million by 2034, according to a new study by Polaris Market Research. The report "Asia Pacific SGLT2 Inhibitors Market Size, Share, Trends, Industry Analysis Report: By Indication (Cardiovascular, Chronic Kidney Disease (CKD) Type 2 Diabetes, and Others), Drug, Distribution Channel, and Country (China, Japan, India, Malaysia, South Korea, Indonesia, Australia, Vietnam, and Rest of Asia Pacific) - Market Forecast, 2025- 2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The SGLT2 inhibitors market in Asia Pacific is experiencing significant growth, driven by the rising prevalence of type 2 diabetes. Lifestyle changes, urbanization, and an aging population are contributing to increased obesity rates and sedentary behaviors, leading to a higher risk of diabetes. As a result, there is a considerable focus on preventive healthcare measures, with governments and healthcare organizations actively promoting early diagnosis and effective management of diabetes.
The rapid economic growth in many Asia Pacific countries is leading to substantial improvements in healthcare infrastructure. Increased investment in healthcare facilities and rising disposable incomes are making advanced diabetes treatments more accessible, thereby driving the demand for healthcare services, including the use of SGLT2 inhibitors for diabetes management.
The Asia Pacific SGLT2 inhibitors market demand is further supported by the heightened awareness of the proven efficacy and additional benefits of SGLT2 inhibitors. These inhibitors are known for effectively reducing blood glucose levels, managing type 2 diabetes, promoting weight loss, and reducing the risk of cardiovascular events, making them a desirable option for both patients and healthcare providers.
Additionally, Asia Pacific has a large population with a high genetic predisposition to diabetes, particularly in countries like India and China. This genetic susceptibility, combined with environmental factors, is contributing to the growing demand for effective diabetes treatments, including SGLT2 inhibitors.
Key Highlights of Asia Pacific SGLT2 Inhibitors Market Report
Based on indication, the type 2 diabetes segment accounted for the largest revenue share in 2023. The rising number of type 2 diabetes cases in Asia Pacific due to changing lifestyles, urbanization, and dietary habits is driving significant demand for effective diabetes management solutions, including SGLT2 inhibitors.
Based on distribution channel, the hospital pharmacies segment is projected to register the fastest growth from 2024 to 2032. With the increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer, there is a growing need for comprehensive and continuous medical care. Hospital pharmacies play a crucial role in managing these conditions by providing necessary medications and ensuring proper drug administration.
In 2023, China accounted for the largest market share in the Asia Pacific SGLT2 inhibitors market due to government initiatives, healthcare reforms, and heightened research and development efforts focused on diabetes management.
AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.); Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Sanofi, Pfizer Inc.; Lupin; and Cipla limited. are a few of the key players in the market.
Polaris Market Research has segmented the Asia Pacific SGLT2 inhibitors market research report on the basis of indication, drug, distribution channel, and country:
By Indication Outlook (Revenue - USD Million, 2020-2034)
- Cardiovascular
- Chronic Kidney Disease (CKD)
- Type 2 Diabetes
- Others
By Drug Outlook (Revenue - USD Mllion, 2020-2034)
- Farxiga (Dapagliflozin)
- Inpefa (Sotagliflozin)
- Invokana (Canagliflozin)
- Jardiance (Empagliflozin)
- Qtern (Dapagliflozin/Saxagliptin)
- Other SGLT2 Inhibitors
By Distribution Channel Outlook (Revenue - USD Million, 2020-2034)
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
By Country Outlook (Revenue - USD Million, 2020-2034)
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Asia SGLT2 Inhibitors Market Insights
- 4.1. SGLT2 Inhibitors Market - Market Snapshot
- 4.2. SGLT2 Inhibitors Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing Prevalence of Diabetes
- 4.2.1.2. The Rapid Urbanization
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Regulatory and Approval Barriers
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. SGLT2 Inhibitors Market Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Asia SGLT2 Inhibitors Market, by Indication
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Asia SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 5.3. Cardiovascular
- 5.3.1. Asia SGLT2 Inhibitors Market, by Cardiovascular, by Country, 2020-2034 (USD Million)
- 5.4. Chronic Kidney Disease (CKD)
- 5.4.1. Asia SGLT2 Inhibitors Market, by Chronic Kidney Disease (CKD), by Country, 2020-2034 (USD Million)
- 5.5. Type 2 Diabetes
- 5.5.1. Asia SGLT2 Inhibitors Market, by Type 2 Diabetes, by Country, 2020-2034 (USD Million)
- 5.6. Others
- 5.6.1. Asia SGLT2 Inhibitors Market, by Shaving Lotions & Creams, by Country, 2020-2034 (USD Million)
6. Asia SGLT2 Inhibitors Market, by Drug
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Asia SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 6.3. Farxiga (Dapagliflozin)
- 6.3.1. Asia SGLT2 Inhibitors Market, by Farxiga (Dapagliflozin), by Country, 2020-2034 (USD Million)
- 6.4. Inpefa (Sotagliflozin)
- 6.4.1. Asia SGLT2 Inhibitors Market, by Inpefa (Sotagliflozin), by Country, 2020-2034 (USD Million)
- 6.5. Invokana (Canagliflozin)
- 6.5.1. Asia SGLT2 Inhibitors Market, by Invokana (Canagliflozin), by Country, 2020-2034 (USD Million)
- 6.6. Jardiance (Empagliflozin)
- 6.6.1. Asia SGLT2 Inhibitors Market, by Jardiance (Empagliflozin), by Country, 2020-2034 (USD Million)
- 6.7. Qtern (Dapagliflozin/Saxagliptin)
- 6.7.1. Asia SGLT2 Inhibitors Market, by Qtern (Dapagliflozin/Saxagliptin), by Country, 2020-2034 (USD Million)
- 6.8. Other SGLT2 Inhibitors
- 6.8.1. Asia SGLT2 Inhibitors Market, by Other SGLT2 Inhibitors, by Country, 2020-2034 (USD Million)
7. Asia SGLT2 Inhibitors Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Asia SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.3. Hospital Pharmacies
- 7.3.1. Asia SGLT2 Inhibitors Market, by Hospital Pharmacies, by Country, 2020-2034 (USD Million)
- 7.4. Online Pharmacies
- 7.4.1. Asia SGLT2 Inhibitors Market, by Online Pharmacies, by Country, 2020-2034 (USD Million)
- 7.5. Retail Pharmacies
- 7.5.1. Asia SGLT2 Inhibitors Market, by Retail Pharmacies, by Country, 2020-2034 (USD Million)
8. Asia SGLT2 Inhibitors Market, by Country
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. SGLT2 Inhibitors Market Assessment, By Country, 2020-2034 (USD Million)
- 8.3. SGLT2 Inhibitors Market - Asia Pacific
- 8.3.1. Asia Pacific: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 8.3.2. Asia Pacific: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 8.3.3. Asia Pacific: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.4. SGLT2 Inhibitors Market - China
- 8.3.4.1. China: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 8.3.4.2. China: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 8.3.4.3. China: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.5. SGLT2 Inhibitors Market - India
- 8.3.5.1. India: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 8.3.5.2. India: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 8.3.5.3. India: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.6. SGLT2 Inhibitors Market - Malaysia
- 8.3.6.1. Malaysia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 8.3.6.2. Malaysia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 8.3.6.3. Malaysia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.7. SGLT2 Inhibitors Market - Japan
- 8.3.7.1. Japan: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 8.3.7.2. Japan: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 8.3.7.3. Japan: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.8. SGLT2 Inhibitors Market - Indonesia
- 8.3.8.1. Indonesia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 8.3.8.2. Indonesia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 8.3.8.3. Indonesia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.9. SGLT2 Inhibitors Market - South Korea
- 8.3.9.1. South Korea: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 8.3.9.2. South Korea: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 8.3.9.3. South Korea: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.10. SGLT2 Inhibitors Market - Australia
- 8.3.10.1. Australia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 8.3.10.2. Australia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 8.3.10.3. Australia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.11. SGLT2 Inhibitors Market - Rest of Asia Pacific
- 8.3.11.1. Rest of Asia Pacific: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 8.3.11.2. Rest of Asia Pacific: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 8.3.11.3. Rest of Asia Pacific: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. AstraZeneca
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Boehringer Ingelheim International GmbH
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Bristol-Myers Squibb Company
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Eli Lilly and Company
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Glenmark Pharmaceuticals Ltd.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Johnson & Johnson Inc. (Janssen Pharmaceuticals, Inc.)
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Lexicon Pharmaceuticals, Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Merck & Co., Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Sanofi
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Pfizer Inc.
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Lupin
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
- 10.12. Cipla Limited
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
List of Tables:
- Table 1 Asia Pacific: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- Table 2 Asia Pacific: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- Table 3 Asia Pacific: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- Table 4 China: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- Table 5 China: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- Table 6 China: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- Table 7 India: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- Table 8 India: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- Table 9 India: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- Table 10 Malaysia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- Table 11 Malaysia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- Table 12 Malaysia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- Table 13 Japan: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- Table 14 Japan: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- Table 15 Japan: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- Table 16 Indonesia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- Table 17 Indonesia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- Table 18 Indonesia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- Table 19 South Korea: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- Table 20 South Korea: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- Table 21 South Korea: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- Table 22 Australia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- Table 23 Australia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- Table 24 Australia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- Table 25 Vietnam: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- Table 26 Vietnam: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- Table 27 Vietnam: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- Table 28 Rest of Asia Pacific: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- Table 29 Rest of Asia Pacific: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- Table 30 Rest of Asia Pacific: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
List of Figures:
- Figure 1. Asia SGLT2 Inhibitors Market, 2020-2034 (USD Million)
- Figure 2. Integrated Ecosystem
- Figure 3. Research Methodology: Top-Down & Bottom-Up Price
- Figure 4. Market by Country
- Figure 5. Porter's Five Forces
- Figure 6. Market by Indication
- Figure 7. Asia SGLT2 Inhibitors Market, by Indication, 2024 & 2034 (USD Million)
- Figure 8. Market by Drug
- Figure 9. Asia SGLT2 Inhibitors Market, by Drug, 2024 & 2034 (USD Million)
- Figure 10. Market by Distribution Channel
- Figure 11. Asia SGLT2 Inhibitors Market, by Distribution Channel, 2024 & 2034 (USD Million)
